For this reason the cancer stem cell-like phenotype commonly observed in IBC tumors may contribute to their aggressive nature but also may offer itself novel therapeutic strategies to the selective targeting of CD44+/CD24− CSCs from bulk tumors. The gene discussed is CD44; the disease is inflammatory breast carcinoma.